Progress of molecular targeted therapies for advanced renal cell carcinoma

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Conti, Alessandro ^a   Santoni, Matteo ^a   Amantini, Consuelo ^b   Burattini, Luciano ^a   Berardi, Rossana ^a   Santoni, Giorgio ^b   Cascinu, Stefano ^a   Muzzonigro, Giovanni ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFLIBERCEPT; APITOLISIB; AXITINIB; AZD 8055; BRIVANIB; CEDIRANIB; CRIZOTINIB; DOVITINIB; EVEROLIMUS; GIRENTUXIMAB; LENVATINIB; LINIFANIB; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; PANITUMUMAB; REGORAFENIB; RIDAFOROLIMUS; SARACATINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TREBANANIB; UNINDEXED DRUG; VANDETANIB; VOLOCIXIMAB; VORINOSTAT; VORSETUZUMAB MAFODOTIN; CARBANILAMIDE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; CANCER STAGING; DRUG ANTAGONISM; GENETICS; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; QUINAZOLINES; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884889096     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/419176     Document Type: Review

References (60)

1. Zimmer M., Doucette D., Siddiqui N., Iliopoulos O., Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumors. Molecular Cancer Research 2004 2 2 89 95 2-s2.0-1342280515 (Pubitemid 38250425)
2. Rini B. I., Small E. J., Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. Journal of Clinical Oncology 2005 23 5 1028 1043 2-s2.0-14644415949 10.1200/JCO.2005.01.186 (Pubitemid 46202321)
3. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 2-s2.0-0142166332 (Pubitemid 37328811)
4. Podar K., Anderson K. C., A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 2010 9 9 1722 1728 2-s2.0-77953597349 10.4161/cc.9.9.11358
5. Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J., Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999 284 5422 1994 1998 2-s2.0-0033580889 10.1126/science.284.5422.1994 (Pubitemid 29309448)
6. Hemmerlein B., Kugler A., Özisik R., Ringert R.-H., Radzun H.-J., Thelen P., Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Archiv 2001 439 5 645 652 2-s2.0-0035166258 (Pubitemid 33071203)
7. Tsuchiya N., Sato K., Akao T., Kakinuma H., Sasaki R., Shimoda N., Satoh S., Habuchi T., Ogawa O., Kato T., Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohoku Journal of Experimental Medicine 2001 195 2 101 113 2-s2.0-0035570863 10.1620/tjem.195.101 (Pubitemid 34223729)
8. Bergers G., Benjamin L. E., Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 2003 3 6 401 410 2-s2.0-0037967272 10.1038/nrc1093 (Pubitemid 37328844)
9. Na X., Wu G., Ryan C. K., Schoen S. R., Di'Santagnese P. A., Messing E. M., Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 α expression in renal cell carcinomas. Journal of Urology 2003 170 2 I 588 592 2-s2.0-0038507194 (Pubitemid 36870265)
10. Levy N. S., Chung S., Furneaux H., Levy A. P., Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. The Journal of Biological Chemistry 1998 273 11 6417 6423 2-s2.0-0032513043 10.1074/jbc.273.11.6417 (Pubitemid 28144735)
11. Vroling L., Van Der Veldt A. A. M., De Haas R. R., Haanen J. B. A. G., Schuurhuis G. J., Kuik D. J., Van Cruijsen H., Verheul H. M. W., Van Den Eertwegh A. J. M., Hoekman K., Boven E., Van Hinsbergh V. W. M., Broxterman H. J., Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009 12 1 69 79 2-s2.0-61449179073 10.1007/s10456-009-9133-9
12. Bauer S. M., Bauer R. J., Velazquez O. C., Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vascular and Endovascular Surgery 2005 39 4 293 306 2-s2.0-23044438985 10.1177/153857440503900401 (Pubitemid 41061696)
13. Bompais H., Chagraoui J., Canron X., Crisan M., Liu X. H., Anjo A., Tolla-Le Port C., Leboeuf M., Charbord P., Bikfalvi A., Uzan G., Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 2004 103 7 2577 2584 2-s2.0-12144287668 10.1182/blood-2003-08-2770 (Pubitemid 38393010)
14. + renal progenitor cells contribute to tumor angiogenesis. American Journal of Pathology 2006 169 6 2223 2235 2-s2.0-35348857355 10.2353/ajpath.2006.060498 (Pubitemid 351181980)
15. Rafii S., Avecilla S., Shmelkov S., Shido K., Tejada R., Moore M. A. S., Heissig B., Hattori K., Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Annals of the New York Academy of Sciences 2003 996 49 60 2-s2.0-0038806646 (Pubitemid 36706586)
16. Ceradini D. J., Kulkarni A. R., Callaghan M. J., Tepper O. M., Bastidas N., Kleinman M. E., Capla J. M., Galiano R. D., Levine J. P., Gurtner G. C., Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine 2004 10 8 858 864 2-s2.0-4043184065 10.1038/nm1075 (Pubitemid 39070860)
17. Kaplan R. N., Riba R. D., Zacharoulis S., Bramley A. H., Vincent L., Costa C., MacDonald D. D., Jin D. K., Shido K., Kerns S. A., Zhu Z., Hicklin D., Wu Y., Port J. L., Altorki N., Port E. R., Ruggero D., Shmelkov S. V., Jensen K. K., Rafii S., Lyden D., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005 438 7069 820 827 2-s2.0-28644432204 10.1038/nature04186 (Pubitemid 41753060)
18. Powles T., Chowdhury S., Shamash J., Bazeos A., Gillessen S., Saunders N., Lim L., Sarwar N., Sadev A., Wilson P., Nathan P., Boleti K., Peters J., Agrawal S., Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Annals of Oncology 2011 22 4 815 820 2-s2.0-79953319193 10.1093/annonc/mdq469
19. Parker L. H., Schmidt M., Jin S.-W., Gray A. M., Beis D., Pham T., Frantz G., Palmieri S., Hillan K., Stainier D. Y. R., De Sauvage F. J., Ye W., The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 2004 428 6984 754 758 2-s2.0-11144356184 10.1038/nature02416 (Pubitemid 38514720)
20. Betsholtz C., Lindblom P., Gerhardt H., Role of pericytes in vascular morphogenesis. EXS 2005 94 115 125 2-s2.0-16644381982
21. Carroll V. A., Ashcroft M., Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Research 2008 68 2 545 552 2-s2.0-39049165830 10.1158/0008-5472.CAN-06-4738 (Pubitemid 351380083)
22. Santoni M., Rizzo M., Burattini L., Berardi R., Carteni G., Cascinu S., Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: when is the revolution coming? Current Cancer Drug Targets 2013 13 3 313 325 10.2174/1568009611313030009
23. Rini B. I., Wilding G., Hudes G., Stadler W. M., Kim S., Tarazi J., Rosbrook B., Trask P. C., Wood L., Dutcher J. P., Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of Clinical Oncology 2009 27 27 4462 4468 2-s2.0-70349388719 10.1200/JCO.2008.21.7034
24. Rixe O., Bukowski R. M., Michaelson M. D., Wilding G., Hudes G. R., Bolte O., Motzer R. J., Bycott P., Liau K. F., Freddo J., Trask P. C., Kim S., Rini B. I., Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncology 2007 8 11 975 984 2-s2.0-35448934762 10.1016/S1470-2045(07)70285-1 (Pubitemid 47629888)
25. Rini B. I., Escudier B., Tomczak P., Kaprin A., Szczylik C., Hutson T. E., Michaelson M. D., Gorbunova V. A., Gore M. E., Rusakov I. G., Negrier S., Ou Y.-C., Castellano D., Lim H. Y., Uemura H., Tarazi J., Cella D., Chen C., Rosbrook B., Kim S., Motzer R. J., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. The Lancet 2011 378 9807 1931 1939 2-s2.0-82755183572 10.1016/S0140-6736(11) 61613-9
26. Rini B. I., Grünwald V., Fishman M. N., Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic analyses from a randomized phase II study. Journal of Clinical Oncology. In press
27. Bhargava P., Esteves B., Nosov D. A., Lipatov O. N., Lyulko A. A., Anischenko A. A., Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). Journal of Clinical Oncology. In press
28. Motzer R. J., Nosov D., Eisen T., Bondarenko I. N., Lesovoy V., Lipatov O. N., Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized. Journal of Clinical Oncology. In press
29. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Oncologic DrugsAdvisoryCommittee/UCM350075.pdf
30. Angevin E., Grünwald V., Ravaud A., Castellano D. E., Lin C. C., Gschwend J. E., A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). Journal of Clinical Oncology. In press
31. Welti J. C., Gourlaouen M., Powles T., Kudahetti S. C., Wilson P., Berney D. M., Reynolds A. R., Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011 30 10 1183 1193 2-s2.0-79952538238 10.1038/onc.2010.503
32. Mulders P., Hawkins R., Nathan P., De Jong I., Osanto S., Porfiri E., Protheroe A., Van Herpen C. M. L., Mookerjee B., Pike L., Jürgensmeier J. M., Gore M. E., Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. European Journal of Cancer 2012 48 4 527 537 2-s2.0-84857052966 10.1016/j.ejca.2011.12.022
33. Tannir N. M., Wong Y.-N., Kollmannsberger C. K., Ernstoff M. S., Perry D. J., Appleman L. J., Posadas E. M., Cho D., Choueiri T. K., Coates A., Gupta N., Pradhan R., Qian J., Chen J., Scappaticci F. A., Ricker J. L., Carlson D. M., Dror Michaelson M., Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer 2011 47 18 2706 2714 2-s2.0-82255160698 10.1016/j.ejca.2011.09.002
34. Eisen T., Joensuu H., Nathan P. D., Harper P. G., Wojtukiewicz M. Z., Nicholson S., Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma:a single-group phase 2 trial. The Lancet Oncology 2012 13 10 1055 1062 10.1016/S1470-2045(12)70364-9
35. Jermann M., Stahel R. A., Salzberg M., Cerny T., Joerger M., Gillessen S., Morant R., Egli F., Rhyner K., Bauer J. A., Pless M., A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemotherapy and Pharmacology 2006 57 4 533 539 2-s2.0-30644478919 10.1007/s00280-005-0070-z (Pubitemid 43087597)
36. Shek D., Longmate J., Quinn D. I., Margolin K. A., Twardowski P., Gandara D. R., Frankel P., Pan C.-X., Lara P. N. Jr., A phase II trial of gefitinib and pegylated IFN α in previously treated renal cell carcinoma. International Journal of Clinical Oncology 2011 16 5 494 499 2-s2.0-84857076257
37. Shepard D. R., Cooney M. M., Elson P., Bukowski R. M., Dreicer R., Rini B. I., Garcia J. A., A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Investigational New Drugs 2012 30 1 364 367 2-s2.0-84856535087 10.1007/s10637-010-9516-1
38. Verheul H. M. W., Hammers H., Van Erp K., Wei Y., Sanni T., Salumbides B., Qian D. Z., Yancopoulos G. D., Pili R., Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clinical Cancer Research 2007 13 14 4201 4208 2-s2.0-34547093162 10.1158/1078-0432.CCR-06-2553 (Pubitemid 47105984)
39. Tew W. P., Gordon M., Murren J., Dupont J., Pezzulli S., Aghajanian C., Sabbatini P., Mendelson D., Schwartz L., Gettinger S., Psyrri A., Cedarbaum J. M., Spriggs D. R., Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clinical Cancer Research 2010 16 1 358 366 2-s2.0-74949101370 10.1158/1078-0432.CCR-09-2103
40. Mita M., Rowinsky E., Mita A., Syed S., Chu Q., Goldston M., Phase 1, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (patients) with refractory or advanced malignancies. Journal of Clinical Oncology 2004 22 14 3076
41. Chresta C. M., Davies B. R., Hickson I., Harding T., Cosulich S., Critchlow S. E., Vincent J. P., Ellston R., Jones D., Sini P., James D., Howard Z., Dudley P., Hughes G., Smith L., Maguire S., Hummersone M., Malagu K., Menear K., Jenkins R., Jacobsen M., Smith G. C. M., Guichard S., Pass M., AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Research 2010 70 1 288 298 2-s2.0-75149112670 10.1158/0008-5472.CAN-09-1751
42. Cho D. C., Hutson T. E., Samlowski W., Sportelli P., Somer B., Richards P., Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 2012 118 6055 6062 10.1002/cncr.27668
43. Cho D. C., Cohen M. B., Panka D. J., Collins M., Ghebremichael M., Atkins M. B., Signoretti S., Mier J. W., The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clinical Cancer Research 2010 16 14 3628 3638 2-s2.0-77954746352 10.1158/1078-0432.CCR-09-3022
44. Roulin D., Waselle L., Dormond-Meuwly A., Dufour M., Demartines N., Dormond O., Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Molecular Cancer 2011 10, article 90 2-s2.0-79960683561 10.1186/1476-4598-10-90
45. Rini B., Szczylik C., Tannir N. M., Koralewski P., Tomczak P., Deptala A., AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012 118 6152 6161 10.1002/cncr.27632
46. Atkins M. B., Ravaud A., Gravis G., Drosik K., Demkow T., Tomczak P., Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study. Journal of Clinical Oncology. In press
47. Ramakrishnan V., Bhaskar V., Law D. A., Wong M. H. L., DuBridge R. B., Breinberg D., O'Hara C., Powers D. B., Liu G., Grove J., Hevezi P., Cass K. M., Watson S., Evangelista F., Powers R. A., Finck B., Wills M., Caras I., Fang Y., McDonald D., Johnson D., Murray R., Jeffry U., Preclinical evaluation of an anti- α 5 β 1 integrin antibody as a novel anti-angiogenic agent. Journal of Experimental Therapeutics and Oncology 2006 5 4 273 286 2-s2.0-33749349945 (Pubitemid 44497002)
48. Yazji S., Bukowksi R. M., Kondagunta V., Figlin R., Final results from phase II study of volociximab, an a5B1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). Journal of Clinical Oncology. In press
49. Law C.-L., Gordon K. A., Toki B. E., Yamane A. K., Hering M. A., Cerveny C. G., Petroziello J. M., Ryan M. C., Smith L., Simon R., Sauter G., Oflazoglu E., Doronina S. O., Meyer D. L., Francisco J. A., Carter P., Senter P. D., Copland J. A., Wood C. G., Wahl A. F., Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Research 2006 66 4 2328 2337 2-s2.0-33644505446 10.1158/0008-5472.CAN-05-2883
50. Oosterwijk E., Ruiter D. J., Hoedemaeker Ph. J., Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. International Journal of Cancer 1986 38 4 489 494 2-s2.0-0022502868 (Pubitemid 16006918)
51. Liu Z., Smyth F. E., Renner C., Lee F.-T., Oosterwijk E., Scott A. M., Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunology, Immunotherapy 2002 51 3 171 177 2-s2.0-0036217460 10.1007/s00262-002-0268-4 (Pubitemid 34298113)
52. Shao Y., Gao Z., Marks P. A., Jiang X., Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2004 101 52 18030 18035 2-s2.0-11144221007 10.1073/pnas.0408345102 (Pubitemid 40054069)
53. Rocchi P., Tonelli R., Camerin C., Purgato S., Fronza R., Bianucci F., Guerra F., Pession A., Ferreri A. M., p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncology Reports 2005 13 6 1139 1144 2-s2.0-24044478600
54. Wang H., Zhou W., Zheng Z., Zhang P., Tu B., He Q., Zhu W.-G., The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair 2012 11 2 146 156 2-s2.0-84855855321 10.1016/j.dnarep.2011. 10.014
55. Hainsworth J. D., Infante J. R., Spigel D. R., Arrowsmith E. R., Boccia R. V., Burris H. A., A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Investigation 2011 29 7 451 455 2-s2.0-79960197509 10.3109/07357907.2011.590568
56. Niu G., Wright K. L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L. M., Karras J., Bromberg J., Pardoll D., Jove R., Yu H., Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002 21 13 2000 2008 2-s2.0-0037150236 10.1038/sj/onc/1205260 (Pubitemid 34270888)
57. Horiguchi A., Asano T., Kuroda K., Sato A., Asakuma J., Ito K., Hayakawa M., Sumitomo M., Asano T., STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. British Journal of Cancer 2010 102 11 1592 1599 2-s2.0-77952888131 10.1038/sj.bjc.6605691
58. Ireson C. R., Kelland L. R., Discovery and development of anticancer aptamers. Molecular Cancer Therapeutics 2006 5 12 2957 2962 2-s2.0-33846252731 10.1158/1535-7163.MCT-06-0172 (Pubitemid 46092036)
59. Ginisty H., Sicard H., Roger B., Bouvet P., Structure and functions of nucleolin. Journal of Cell Science 1999 112 6 761 772 2-s2.0-0032921853 (Pubitemid 29179310)
60. Soundararajan S., Chen W., Spicer E. K., Courtenay-Luck N., Fernandes D. J., The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Research 2008 68 7 2358 2365 2-s2.0-42049124068 10.1158/0008-5472.CAN-07-5723 (Pubitemid 351521810)